Hypha Labs, Inc.
Hypha Labs, Inc., engages in the research, development, and commercialization of a bioreactor in the United States. It offers Hypha Micropearl bioreactor, a home appliance designed to accelerate the production of beneficial mushrooms for human consumption. Hypha Labs, Inc. was incorporated in 2010 and is headquartered in Las Vegas, Nevada.
Hypha Labs, Inc. (FUNI) - Net Assets
Latest net assets as of December 2025: $-2.35 Million USD
Based on the latest financial reports, Hypha Labs, Inc. (FUNI) has net assets worth $-2.35 Million USD as of December 2025.
Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets ($391.60K) and total liabilities ($2.74 Million). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | $-2.35 Million |
| % of Total Assets | -600.48% |
| Annual Growth Rate | N/A |
| 5-Year Change | N/A |
| 10-Year Change | -270.3% |
| Growth Volatility | 480.03 |
Hypha Labs, Inc. - Net Assets Trend (2011–2025)
This chart illustrates how Hypha Labs, Inc.'s net assets have evolved over time, based on quarterly financial data. Explore and compare other companies by net assets.
Annual Net Assets for Hypha Labs, Inc. (2011–2025)
The table below shows the annual net assets of Hypha Labs, Inc. from 2011 to 2025.
| Year | Net Assets | Change |
|---|---|---|
| 2025-09-30 | $-2.10 Million | -126.95% |
| 2024-09-30 | $-926.69K | +50.48% |
| 2023-09-30 | $-1.87 Million | +31.77% |
| 2022-09-30 | $-2.74 Million | -160.40% |
| 2021-09-30 | $-1.05 Million | +3.29% |
| 2020-09-30 | $-1.09 Million | -355.75% |
| 2019-09-30 | $425.87K | -58.03% |
| 2018-09-30 | $1.01 Million | -27.90% |
| 2017-09-30 | $1.41 Million | +13.95% |
| 2016-09-30 | $1.23 Million | -38.73% |
| 2015-09-30 | $2.02 Million | -63.26% |
| 2014-09-30 | $5.49 Million | +1103.23% |
| 2013-09-30 | $-546.92K | -105.65% |
| 2012-09-30 | $-265.95K | -1421.43% |
| 2011-09-30 | $20.13K | -- |
Equity Component Analysis
This analysis shows how different components contribute to Hypha Labs, Inc.'s total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have decreased by 2362177800.0% over the analyzed period, potentially due to dividend distributions or operating losses.
Current Equity Component Breakdown (September 2025)
| Component | Amount | Percentage |
|---|---|---|
| Common Stock | $147.12K | % |
| Other Components | $21.40 Million | % |
| Total Equity | $-2.10 Million | 100.00% |
Hypha Labs, Inc. Competitors by Market Cap
The table below lists competitors of Hypha Labs, Inc. ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
Herbal Dispatch Inc.
F:HA9
|
$3.75 Million |
|
Renforth Resources Inc
PINK:RFHRF
|
$3.75 Million |
|
Aspen Group Inc
OTCQB:ASPU
|
$3.75 Million |
|
Palram
TA:PLRM
|
$3.75 Million |
|
CA Sales Holdings Ltd.
JSE:CAA
|
$3.75 Million |
|
Vision Lithium Inc
OTCQB:ABEPF
|
$3.75 Million |
|
Design Co. Ltd
KQ:227100
|
$3.74 Million |
|
Hultström Group B
ST:HULT-B
|
$3.74 Million |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in Hypha Labs, Inc.'s equity between the two most recent reporting periods.
Equity Growth Insights
- From 2024 to 2025, total equity changed from -926,693 to -2,103,169, a change of -1,176,476.
- Net loss of 3,101,901 reduced equity.
- New share issuances of 76,396 increased equity.
- Other factors increased equity by 1,849,029.
Equity Change Factors (2024 to 2025)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | $-3.10 Million | -147.49% |
| Share Issuances | $76.40K | +3.63% |
| Other Changes | $1.85 Million | +87.92% |
| Total Change | $- | % |
Book Value vs Market Value Analysis
This analysis compares Hypha Labs, Inc.'s book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 2011-09-30 | $0.04 | $0.03 | x |
| 2012-09-30 | $-0.49 | $0.03 | x |
| 2013-09-30 | $-0.99 | $0.03 | x |
| 2014-09-30 | $2.38 | $0.03 | x |
| 2015-09-30 | $0.24 | $0.03 | x |
| 2016-09-30 | $0.07 | $0.03 | x |
| 2017-09-30 | $0.05 | $0.03 | x |
| 2018-09-30 | $0.03 | $0.03 | x |
| 2019-09-30 | $0.01 | $0.03 | x |
| 2020-09-30 | $-0.02 | $0.03 | x |
| 2021-09-30 | $-0.02 | $0.03 | x |
| 2022-09-30 | $-0.03 | $0.03 | x |
| 2023-09-30 | $-0.02 | $0.03 | x |
| 2024-09-30 | $-0.01 | $0.03 | x |
| 2025-09-30 | $-0.02 | $0.03 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently Hypha Labs, Inc. utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): 0.00%
- The company may be facing challenges in efficiently utilizing shareholder equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: 0.00%
- • Asset Turnover: 0.00x
- • Equity Multiplier: 0.00x
- Recent ROE (0.00%) is above the historical average (-88.74%), indicating improving capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 2011 | -136.88% | -28.72% | 0.36x | 13.15x | $-29.56K |
| 2012 | 0.00% | -83.23% | 1.12x | 0.00x | $-299.40K |
| 2013 | 0.00% | -58.18% | 2.22x | 0.00x | $-275.31K |
| 2014 | -48.57% | -5154.62% | 0.01x | 0.97x | $-3.42 Million |
| 2015 | -183.62% | -26933.60% | 0.01x | 0.92x | $-4.57 Million |
| 2016 | -299.52% | -451.88% | 0.57x | 1.17x | $-3.82 Million |
| 2017 | -75.68% | -56.11% | 1.21x | 1.12x | $-1.21 Million |
| 2018 | -163.02% | -58.24% | 2.03x | 1.38x | $-1.76 Million |
| 2019 | -423.84% | -70.70% | 1.88x | 3.18x | $-1.85 Million |
| 2020 | 0.00% | -89.70% | 1.44x | 0.00x | $-2.20 Million |
| 2021 | 0.00% | -27.44% | 1.33x | 0.00x | $-581.67K |
| 2022 | 0.00% | -76.19% | 2.02x | 0.00x | $-1.82 Million |
| 2023 | 0.00% | 0.00% | 0.00x | 0.00x | $433.92K |
| 2024 | 0.00% | 0.00% | 0.00x | 0.00x | $-692.33K |
| 2025 | 0.00% | 0.00% | 0.00x | 0.00x | $-2.89 Million |
Industry Comparison
This section compares Hypha Labs, Inc.'s net assets metrics with peer companies in the Diagnostics & Research industry.
Industry Context
- Industry: Diagnostics & Research
- Average net assets among peers: $867,957,363
- Average return on equity (ROE) among peers: -141.01%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| Hypha Labs, Inc. (FUNI) | $-2.35 Million | -136.88% | N/A | $3.75 Million |
| Agilent Technologies Inc (A) | $4.57 Billion | 6.91% | 0.87x | $31.45 Billion |
| Amer Bio Medica (ABMC) | $-944.00K | 0.00% | 0.00x | $3.55K |
| ADCNF (ADCNF) | $612.34 Million | 111.18% | 6.93x | $172.01 Million |
| Advanced Biomed Inc. Common Stock (ADVB) | $3.48 Billion | 0.00% | 0.87x | $1.64 Million |
| ANGLE plc (ANPCF) | $18.44 Million | -77.14% | 0.38x | $34.42 Million |
| SeqLL Inc. (ATLN) | $4.37 Million | -93.77% | 0.93x | $36.19K |
| Avricore Health Inc (AVCRF) | $3.35 Million | -65.62% | 0.06x | $3.22 Million |
| Aspira Womens Health Inc (AWH) | $4.67 Million | -153.12% | 0.85x | $664.47K |
| Biodesix Inc (BDSX) | $4.58 Million | -1138.56% | 20.64x | $48.86 Million |
| bioAffinity Technologies, Inc. (BIAF) | $-15.79 Million | 0.00% | 0.00x | $5.08 Million |